197 related articles for article (PubMed ID: 27343991)
1. Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study.
Dalenc F; Iuliano L; Filleron T; Zerbinati C; Voisin M; Arellano C; Chatelut E; Marquet P; Samadi M; Roché H; Poirot M; Silvente-Poirot S
J Steroid Biochem Mol Biol; 2017 May; 169():210-218. PubMed ID: 27343991
[TBL] [Abstract][Full Text] [Related]
2. Plasma oxysterol levels in luminal subtype breast cancer patients are associated with clinical data.
Kloudova-Spalenkova A; Ueng YF; Wei S; Kopeckova K; Peter Guengerich F; Soucek P
J Steroid Biochem Mol Biol; 2020 Mar; 197():105566. PubMed ID: 31874216
[TBL] [Abstract][Full Text] [Related]
3. Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition.
Gltick S
Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S321-2. PubMed ID: 16521302
[TBL] [Abstract][Full Text] [Related]
4. Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.
Hubalek M; Oberguggenberger A; Beer B; Meraner V; Sztankay M; Oberacher H; Schubert B; Wildt L; Seeber B; Giesinger J; Kemmler G; Holzner B; Sperner-Unterweger B
Clin Breast Cancer; 2014 Aug; 14(4):291-6. PubMed ID: 24468298
[TBL] [Abstract][Full Text] [Related]
5. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.
Rydén L; Heibert Arnlind M; Vitols S; Höistad M; Ahlgren J
Breast; 2016 Apr; 26():106-14. PubMed ID: 27017249
[TBL] [Abstract][Full Text] [Related]
6. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
7. Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer.
Eggemann H; Altmann U; Costa SD; Ignatov A
J Cancer Res Clin Oncol; 2018 Feb; 144(2):337-341. PubMed ID: 29098396
[TBL] [Abstract][Full Text] [Related]
8. Aromatase inhibitors decrease radiation-induced lung fibrosis: Results of an experimental study.
Altinok AY; Yildirim S; Altug T; Sut N; Ober A; Ozsahin EM; Azria D; Bese NS
Breast; 2016 Aug; 28():174-7. PubMed ID: 27326979
[TBL] [Abstract][Full Text] [Related]
9. Reproducibility of serum oxysterols and lanosterol among postmenopausal women: Results from EPIC-Heidelberg.
Lu DL; Sookthai D; Le Cornet C; Katzke VA; Johnson TS; Kaaks R; Fortner RT
Clin Biochem; 2018 Feb; 52():117-122. PubMed ID: 29108727
[TBL] [Abstract][Full Text] [Related]
10. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
[TBL] [Abstract][Full Text] [Related]
11. Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study.
Ferreira AR; Palha A; Correia L; Filipe P; Rodrigues V; Miranda A; André R; Fernandes J; Gouveia J; Passos-Coelho JL; Moreira A; Brito M; Ribeiro J; Metzger-Filho O; Lin NU; Costa L; Vaz-Luis I
Breast; 2018 Feb; 37():107-113. PubMed ID: 29131988
[TBL] [Abstract][Full Text] [Related]
12. Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?
Aapro M; van de Velde CJ; Markopoulos C; Bartlett JM; Putter H; Coleman RE
Breast; 2013 Aug; 22(4):488-94. PubMed ID: 23454040
[TBL] [Abstract][Full Text] [Related]
13. Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.
Motomura K; Ishitobi M; Komoike Y; Koyama H; Nagase H; Inaji H; Noguchi S
Oncology; 2010; 79(1-2):55-61. PubMed ID: 21071990
[TBL] [Abstract][Full Text] [Related]
14. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
[TBL] [Abstract][Full Text] [Related]
15. Improvement of 5,6α-epoxycholesterol, 5,6β-epoxycholesterol, cholestane-3β,5α,6β-triol and 6-oxo-cholestan-3β,5α-diol recovery for quantification by GC/MS.
Soules R; Noguer E; Iuliano L; Zerbinati C; Leignadier J; Rives A; de Medina P; Silvente-Poirot S; Poirot M
Chem Phys Lipids; 2017 Oct; 207(Pt B):92-98. PubMed ID: 28554594
[TBL] [Abstract][Full Text] [Related]
16. When to start an aromatase inhibitor: now or later?
Doughty JC
J Surg Oncol; 2011 Jun; 103(7):730-8. PubMed ID: 21360530
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
Dubsky PC; Jakesz R; Mlineritsch B; Pöstlberger S; Samonigg H; Kwasny W; Tausch C; Stöger H; Haider K; Fitzal F; Singer CF; Stierer M; Sevelda P; Luschin-Ebengreuth G; Taucher S; Rudas M; Bartsch R; Steger GG; Greil R; Filipcic L; Gnant M
J Clin Oncol; 2012 Mar; 30(7):722-8. PubMed ID: 22271481
[TBL] [Abstract][Full Text] [Related]
18. The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study.
Akyol M; Demir L; Alacacioglu A; Ellidokuz H; Kucukzeybek Y; Yildiz Y; Gumus Z; Bayoglu V; Yildiz I; Salman T; Varol U; Kucukzeybek B; Demir L; Dirican A; Sutcu R; Tarhan MO
Chemotherapy; 2016; 61(2):57-64. PubMed ID: 26571369
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer.
Erman A; Nugent A; Amir E; Coyte PC
Breast Cancer Res Treat; 2014 Jun; 145(2):267-79. PubMed ID: 24771048
[TBL] [Abstract][Full Text] [Related]
20. HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
Bartlett JMS; Ahmed I; Regan MM; Sestak I; Mallon EA; Dell'Orto P; Thürlimann B; Seynaeve C; Putter H; Van de Velde CJH; Brookes CL; Forbes JF; Viale G; Cuzick J; Dowsett M; Rea DW;
Eur J Cancer; 2017 Jul; 79():129-138. PubMed ID: 28494403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
